Analysis Novo Nordisk’s Strategic Pivot: A High-Stakes Bet on Liver Disease
Facing significant headwinds in its core business, Danish pharmaceutical giant Novo Nordisk is executing a costly but calculated strategic shift. The company’s management is under pressure to act as prescription...